Insider Transactions in Q1 2024 at Akero Therapeutics, Inc. (AKRO)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 13
2024
|
Jonathan Young Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
651
-0.24%
|
$18,228
$28.33 P/Share
|
|
Mar 13
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
1,969
-0.33%
|
$55,132
$28.33 P/Share
|
|
Mar 13
2024
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
724
-1.44%
|
$20,272
$28.33 P/Share
|
|
Mar 13
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
723
-0.92%
|
$20,244
$28.33 P/Share
|
|
Mar 13
2024
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
619
-0.34%
|
$17,332
$28.33 P/Share
|
|
Mar 04
2024
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
20,646
-20.84%
|
$722,610
$35.49 P/Share
|
|
Mar 04
2024
|
Catriona Yale Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,646
+9.93%
|
$268,398
$13.73 P/Share
|
|
Mar 04
2024
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
75,000
-1.96%
|
$2,475,000
$33.99 P/Share
|
|
Mar 04
2024
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+5.35%
|
$1,350,000
$18.55 P/Share
|
|
Mar 01
2024
|
Jonathan Young Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
83,321
+23.65%
|
$0
$0.62 P/Share
|
|
Jan 02
2024
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+6.34%
|
$0
$0.62 P/Share
|